Myriam Mendila: Yes. So maybe I can take this one. And so the Alex did you want to start?
Alexander Zehnder: Go ahead. I can add.
Myriam Mendila: Okay super. So with MD Anderson of course, we discussed the selection of indications and follow the same approach, where MD Anderson has their priorities, we had our priorities. And then we sort of like look what is in the – where is it overlapping? And so we have agreed already on the indications that we will focus on our collaboration and I don’t recall what our second part of the question.
Unidentified Analyst: Oh, that was it.
Myriam Mendila: Okay. Thank you.
Unidentified Analyst: Thank you.
Operator: Thank you. Our next question comes from Charlie Yang with Bank of America. Please proceed with your question.
Charlie Yang: Great. Thanks for taking the questions. I have a few please. First one is can you just talk about the regulatory pathway for glioblastoma trial. I guess my impression maybe perhaps was that this is going to be more of a proof of concept but your focus will be on the other indications with the other account platforms. But if this a – has – then what would that time line kind of look like? And I guess my second question is just thinking about all the different kind of early-stage programs that you have in the cancer vaccine and thinking about the cash balance and the run rate. How do you think about account prioritization among those programs which one is kind of more important versus the others? And why not just focus on one instead of sort of kind of doing a few.
And lastly just with hiring of kind of new Chief Business Officer, what kind of strategic deals that you – that the company is thinking of in coming perhaps months or quarters? And how should we think about from the therapeutic count standpoint? Thank you.
Alexander Zehnder: Thank you, Charlie. What was…
Myriam Mendila: GBM regulatory. Yes. Maybe I can take the first two Alex and then you can address the third one. So for GBM, as you rightly stated, right, for us this is a proof of principle study. We already announced an earlier call — disclosed in earlier calls that, this is for us a trial where we are using basically our platform in oncology for the very first time. And our intention is to show it’s safe and well tolerated and it’s inducing an immune response against the encoded antigens. We didn’t have and don’t have plans to then — to take this as a pox to proof of concept and then start a Phase II or Phase III program. If — and you never know, right? But if we would see which is unexpected some strong compelling efficacy signal which will take time in the GBM trial because we are here treating patients that have undergone surgery, so they don’t have remaining tumor and hence assessing efficacy will always be based on an endpoint-driven parameters such as disease-free survival or progression-free survival.
But in case with longer follow-up, we would see something compelling, then we will revisit that decision. Right now, we are not considering to take this all the way through clinical development and into Phase III, but again just want to use the GBM data as a proof of principle the platform works in oncology. Then regarding the prioritization of the different oncology programs and the sort of like cash runway we’re having is of course something that will happen once we have the data. Right now, we have the GBM program. We are preparing for another Phase I program with a clinical candidate and the collaboration with MD Anderson is just starting, right? And we need to see, if we can find antigens that will enable us to nominate a candidate. And then again, based on what I described before different parameters, we will see what we can take to the clinics and otherwise prioritized based on the scientific evidence and the signals we’ve seen in terms of what we’ll take into the clinic.
Alexander Zehnder: Thank you, Myriam. And I think the last question was regarding with the incoming of the new CBO, Thaminda and strategic direction for business development or additional partnerships. I think there are a few focus area for us. One being oncology for sure even though, we have announced the collaboration with MD Anderson, this will not preclude us from additional partnerships for these assets, if they make it to through Phase II. So oncology is definitely a big focus for us in looking for additional partnerships. We also still have opportunities on the infectious disease side for programs that are not partnered with GSK. Beyond this in molecular therapies, we have a few programs ongoing that we haven’t fully disclosed, but that could be interested for partnering in selected indications. So, it’s definitely something that we’re looking at very broadly and we are engaged and Thaminda coming on board, we can engage even further on this.
Charlie Yang: Thank you.
Operator: Thank you. And we have reached the end of the question-and-answer session. I’ll now turn the call back over to Sarah Fakih for closing remarks.
Sarah Fakih: Thank you. With this, we would like to conclude this conference call. Thank you very much for your participation. Stay safe and please don’t hesitate to contact us should you have any further questions. Thank you and goodbye.
Operator: Thank you. This concludes today’s conference and you may disconnect your lines at this time. Thank you for your participation.
